Oric Pharmaceuticals, Inc.
ORIC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001796280
In the last 90 days, Oric Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 5 sales; 180 institutions reported holding it in 13F filings for Q2 2026, worth $1.34B in total; Viking Global Investors is the only superinvestor holding it.
13F holders, Q1 2022
Institutional positions in Oric Pharmaceuticals, Inc. as of Mar 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 101
- +21 vs. Q4 2021
- Shares held
- 34.0M
- −840.1K (−2.4%) vs. Q4 2021
- Total value
- $181.7M
- −$330.5M (−64.5%) vs. Q4 2021
- New holders
- 33
- 22 more added
- Sold out
- 12
- 28 more reduced
Compare with Q4 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ORIC on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 180 | $1.34B |
| Q1 2026 | 182 | $1.51B |
| Q4 2025 | 165 | $979.6M |
| Q3 2025 | 152 | $1.28B |
| Q2 2025 | 142 | $947.6M |
| Q1 2025 | 143 | $442.0M |
| Q4 2024 | 129 | $611.7M |
| Q3 2024 | 122 | $715.1M |
| Q2 2024 | 113 | $478.3M |
| Q1 2024 | 112 | $879.3M |
| Q4 2023 | 92 | $465.9M |
| Q3 2023 | 90 | $290.7M |
| Q2 2023 | 83 | $353.4M |
| Q1 2023 | 71 | $188.5M |
| Q4 2022 | 64 | $192.1M |
| Q3 2022 | 76 | $104.6M |
| Q2 2022 | 83 | $147.1M |
| Q1 2022 | 101 | $181.7M |
| Q4 2021 | 80 | $512.1M |
| Q3 2021 | 82 | $762.1M |
| Q2 2021 | 78 | $639.4M |
| Q1 2021 | 82 | $874.3M |
Institutions, Q1 2022
Shares, value and share of portfolio for each institution holding Oric Pharmaceuticals, Inc.; share changes are against Q4 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 4,418,413 | $23.6M | 0.00% | −1,488,866−25.2% | Reduced |
| Jennison Associates LLC | 0 | $0 | 0.00% | −985,072−100.0% | Sold out |
| Rafferty Asset Management, LLC | 0 | $0 | 0.00% | −68,423−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −62,399−100.0% | Sold out |
| Laurion Capital Management LP | 0 | $0 | 0.00% | −47,821−100.0% | Sold out |
| Prudential Financial Inc | 0 | $0 | 0.00% | −35,230−100.0% | Sold out |
| M&T Bank Corp | 0 | $0 | 0.00% | −20,536−100.0% | Sold out |
| SG Americas Securities, LLC | 0 | $0 | 0.00% | −13,650−100.0% | Sold out |
| ProShare Advisors LLC | 0 | $0 | 0.00% | −12,447−100.0% | Sold out |
| MetLife Investment Management | 0 | $0 | 0.00% | −11,317−100.0% | Sold out |
| Metropolitan Life Insurance Co | 0 | $0 | 0.00% | −8,707−100.0% | Sold out |
| Zurcher Kantonalbank (Zurich Cantonalbank) | 0 | $0 | 0.00% | −1,620−100.0% | Sold out |
| Parallel Advisors, LLC | 0 | $0 | 0.00% | −628−100.0% | Sold out |